<DOC>
	<DOCNO>NCT02509975</DOCNO>
	<brief_summary>This prospective , pilot , open-label , uncontrolled , non-randomized safety effectiveness study OCL 503 men BPH .</brief_summary>
	<brief_title>Safety Efficacy OCL 503 Prostate Artery Embolization</brief_title>
	<detailed_description>Prior enter study , patient undergo pre-study assessment include compliance inclusion exclusion criterion , laboratory assessment , IPSS , uroflowmetry , IIEF , MRI pelvic image . Following conventional catheter angiography cone-beam CT confirm catheter placement prostatic vasculature , patient undergo transarterial embolization OCL 503 . OCL 503 administered intra-arterially via microcatheter stasis blood flow . Patient assessment include blood work , IPSS , uroflowmetry , IIEF , MRI patient interview conduct 3 month , 6 month , 12 month post embolization .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<criteria>Patient receive diagnosis BPH moderate severe LUTS , determine IPSS Patient great 50 year age Patient pelvic examination within past 6 month Patient refractory medical therapy last 6 month , refuse medical therapy Patient Qmax 15 mL/s acute urinary retention Prostate large 40 cubic centimetre Patient willing able provide write , informed consent Known malignancy Serum PSA &gt; 10 ng/mL screen Advanced atherosclerosis tortuosity iliac artery Prior transurethral resection prostate ( TURP ) Post void retention ( PVR ) &gt; 250 mL Chronic use metronidizole Phytotherapy BPH within last two week screen visit Secondary renal insufficiency due prostatic obstruction Chronic renal failure ( GSR &lt; 60 ) Large bladder diverticulum bladder stone Claustrophobia contraindication relate perform MRI Compromised hematopoietic function Anaphylactic reaction drug anesthetic , allergic reaction iodine contrast medium Investigational drug experimental therapy past 4 week Abnormal coagulation profile Allergy bovine collagen</criteria>
	<gender>Male</gender>
	<minimum_age>51 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>embolization</keyword>
	<keyword>prostate</keyword>
</DOC>